Neurogene (NGNE) Times Interest Earned (2013 - 2026)
Neurogene's (NGNE) quarterly Times Interest Earned came in at -$4.63 in Q1 2026, up 87.49% YoY from -$2.47 in Q1 2025, and up 96.2% on a QoQ basis from -$121.81 in Q4 2025.
Powered by 
Analysis
Neurogene (NGNE) Times Interest Earned (2013 - 2026) Analysis & Trends
Neurogene (NGNE) has 13 years of Times Interest Earned data on file, last reported at -$4.63 in Q1 2026.
- Quarterly Times Interest Earned rose 87.49% year-over-year to -$4.63 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$15.38 (up 88.0% YoY) and the FY2025 annual result came in at -$0.74, down 2.89% from the prior year.
- Times Interest Earned climbed to -$4.63 in Q1 2026, from -$121.81 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of -$0.31 in Q4 2022 to a low of -$10756.0 in Q4 2024.
- A 5-year average of -$1272.4 and a median of -$121.81 in 2025 frame the typical range for Times Interest Earned.
- Annual changes were most pronounced in 2023 — Times Interest Earned slumped 253488.13% — and 2024, when it soared 99.99%.
- Tracing NGNE's Times Interest Earned over 5 years: stood at -$0.31 in 2022, then tumbled by 253488.13% to -$775.42 in 2023, then tumbled by 1287.12% to -$10756.0 in 2024, then soared by 98.87% to -$121.81 in 2025, then surged by 96.2% to -$4.63 in 2026.
- The last three Times Interest Earned figures came in at -$4.63 (Q1 2026), -$121.81 (Q4 2025), and -$8.21 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -21.24 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.42 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.08 |
| 10 | Neurogene | 864.53 Mn | 864.53 Mn | - | -5,238.57 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -5,238.57 |
| Mar 31, 2026 | -3,705.44 |
| Dec 31, 2025 | -809.68 |
| Sep 30, 2025 | -566.62 |
| Jun 30, 2025 | -352.45 |
| Mar 31, 2025 | -323.99 |
| Dec 31, 2024 | -51.96 |
| Sep 30, 2024 | -1,167.37 |
| Jun 30, 2024 | -37.77 |
| Mar 31, 2024 | -31.19 |
| Dec 31, 2023 | -866.65 |
| Sep 30, 2023 | -3,804.75 |
| Jun 30, 2023 | -3,149.00 |
| Mar 31, 2023 | -4,345.00 |
| Mar 31, 2020 | -453.55 |
| Sep 30, 2015 | -1,257.75 |
| Jun 30, 2015 | -949.00 |
| Mar 31, 2015 | -1,067.67 |
| Dec 31, 2014 | 1,012.25 |
| Sep 30, 2014 | -3,141.00 |